I agree that this site is using cookies. You can find further informations here.
X
de Jong, Lisa A
778  results:
Search for persons X
?
1

Evaluating the Cost-Utility of Continuous Glucose Monitorin..:

de Jong, Lisa A. ; Li, Xinyu ; Emamipour, Sajad...
PharmacoEconomics.  , 2024
Link: https://doi.org/10.1007/..
 
?
2

Differences in evidentiary requirements for oncology drug e..:

Wolters, Sharon ; de Jong, Lisa A ; Jansen, Christel..
Expert Review of Pharmacoeconomics & Outcomes Research.  24 (2023)  2 - p. 251-265 , 2023
Link: https://doi.org/10.1080/..
 
?
3

Budget and health impact of switching eligible patients wit..:

Fens, Tanja ; de Jong, Lisa ; Kappelhoff, Bregt..
Journal of Market Access & Health Policy.  11 (2023)  1 - p. , 2023
Link: https://doi.org/10.1080/..
 
?
4

Cost-effectiveness model of trastuzumab deruxtecan as secon..:

Paulissen, Jeroen H. J. ; Seddik, Ahmed H. ; Dunton, Kyle J....
The European Journal of Health Economics.  25 (2023)  4 - p. 689-699 , 2023
Link: https://doi.org/10.1007/..
 
?
5

Correction: Cost-effectiveness of apixaban compared to othe..:

de Jong, Lisa A. ; Groeneveld, Jessie ; Stevanovic, Jelena...
PLOS ONE.  17 (2022)  3 - p. e0266625 , 2022
Link: https://doi.org/10.1371/..
 
?
6

Author's Reply:

van der Pol, Simon ; de Jong, Lisa A. ; Vemer, Pepijn..
Value in Health.  23 (2020)  5 - p. 675-676 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Cost-effectiveness analysis and budget impact of rivaroxaba..:

de Jong, Lisa A ; van der Velden, Annette W G ; Hulst, Marinus van.
BMJ Open.  10 (2020)  11 - p. e039057 , 2020
Link: https://doi.org/10.1136/..
 
?
8

Cost-Effectiveness of Sacubitril/Valsartan in Germany: An A..:

van der Pol, Simon ; de Jong, Lisa A. ; Vemer, Pepijn..
Value in Health.  22 (2019)  10 - p. 1119-1127 , 2019
Link: https://doi.org/10.1016/..
 
?
9

Cost-effectiveness of apixaban compared to other anticoagul..:

de Jong, Lisa A. ; Groeneveld, Jessie ; Stevanovic, Jelena...
PLOS ONE.  14 (2019)  9 - p. e0222658 , 2019
Link: https://doi.org/10.1371/..
 
?
10

Budget Impact Analysis of Metformin Sustained Release for t..:

Gout-Zwart, Judith J. ; de Jong, Lisa A. ; Saptenno, Lisanne.
PharmacoEconomics - Open.  4 (2019)  2 - p. 321-330 , 2019
Link: https://doi.org/10.1007/..
 
?
11

Health economic evaluation of rivaroxaban in elective cardi..:

Jacobs, Maartje S. ; de Jong, Lisa A. ; Postma, Maarten J...
The European Journal of Health Economics.  19 (2018)  7 - p. 957-965 , 2018
Link: https://www.jstor.org/st..
 
?
12

Extended Treatment with Apixaban for Venous Thromboembolism..:

de Jong, Lisa ; Gout-Zwart, Judith ; Stevanovic, Jelena...
TH Open.  2 (2018)  3 - p. e315-e324 , 2018
Link: https://doi.org/10.1055/..
 
?
13

Cost-effectiveness Analysis for Apixaban in the Acute Treat..:

de Jong, Lisa A. ; Dvortsin, Evgeni ; Janssen, Kristel J..
Clinical Therapeutics.  39 (2017)  2 - p. 288-302.e4 , 2017
Link: https://doi.org/10.1016/..
 
?
14

Health economic evaluation of rivaroxaban in elective cardi..:

Jacobs, Maartje S. ; de Jong, Lisa A. ; Postma, Maarten J...
The European Journal of Health Economics.  19 (2017)  7 - p. 957-965 , 2017
Link: https://doi.org/10.1007/..
 
?
15

Transmural migration and perforation of a levonorgestrel in..:

Ferguson, Carrie Anne ; Costescu, Dustin ; Jamieson, Mary Anne.
Contraception.  93 (2016)  1 - p. 81-86 , 2016
Link: https://doi.org/10.1016/..
 
1-15